OmniAb, Inc.
$4.66-$0.37 (-7.4%)
Last close · Data as of Nov 20, 2026
- Market cap
- $385.6M
- P/E
- -6.0x
- EV / EBITDA
- -8.1x
- Revenue
- $18.7M
- Net margin
- -347.0%
- ROCE
- -24.2%
Price chart
Technical chartScreen technicals →+179.0% over the last year
Daily closes.
Go deeper
Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes
Performance
Price return, before dividends, to the 20 Nov 2026 close.
- 1M
- -6.0%
- 3M
- +8.4%
- 6M
- +80.6%
- 1Y
- +179.0%
- 5Y
- Hidden
- This period includes a one-day price step on 2 Nov 2022 that looks like a share split or a similar corporate action. The figure is hidden until the price history is adjusted for it.
52-week range
Day change -$0.37 (-7.4%) from $5.03 to $4.66 · Last close Nov 20, 2026
Best weekday to invest, historically
The same weekly amount in OABI, bought on each weekday since 2021.
News & filings
What OmniAb filed, who traded, and what's next
How to read this
"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.
AI Summary
US StockConcernThe company made a net loss of 64.8 million US dollars in fiscal 2025.
Strengths (1)
- The price is 58.6% above its 200-day average, and the 50-day average is above the 200-day.
Prices to the 20 Nov 2026 close · Financial year: fiscal 2025
Rule-based from financial data. Not advice.
About the company
OmniAb, Inc., a biotechnology company, licenses discovery research technology to pharmaceutical and biotech companies, and academic institutions to enable the discovery of therapeutics in the United States, Europe, Japan, China, and Canada.
Read moreShow less
OmniAb, Inc., a biotechnology company, licenses discovery research technology to pharmaceutical and biotech companies, and academic institutions to enable the discovery of therapeutics in the United States, Europe, Japan, China, and Canada. The company's technology platform creates and screens diverse antibody repertoires to identify optimal antibodies and other target-binding proteins for partners' drug development efforts. Its OmniAb platform's Biological Intelligence powers the immune systems of its proprietary and engineered transgenic animals to create optimized antibody candidates for human therapeutics. The company offers animal-based technologies include OmniRat, OmniChicken, and OmniMouse, which have been genetically modified to generate antibodies with human sequences; OmniFlic, a bispecific rat and OmniClic, a bispecific chicken are designed for discovery of bispecific antibody applications; OmniTaur, which provides cow-inspired antibodies with unique structural characteristics for challenging targets; OmnidAb, an in vivo platform for the discovery of single-domain antibodies based upon a human VH scaffold; and OmniDeep, a suite of in silico, an artificial intelligence (AI) and machine learning tools for therapeutic discovery and optimization through various technologies and capabilities. It has an agreement with mAbsolve Ltd. for its Fc-silencing platform technology to incorporate the STR technology into antibodies that have been generated using OmniAb's antibody discovery platform. OmniAb, Inc. was founded in 2012 and is headquartered in Emeryville, California.
- Sector
- Healthcare
- Shares outstanding
- 144.3M
Key statistics
Screen fundamentals →Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.
Valuation
- Market cap
- $385.6M
- P/E
- -6.0x
- P/B
- 1.4x
- EV / EBITDA
- -8.1x
- EV / Sales
- 20.4x
- P/S
- 20.7x
- 52-week high
- $5.30
- 52-week low
- $1.36
Profitability
- Operating margin
- -369.5%
- Net margin
- -347.0%
- EBITDA margin
- -252.9%
- ROE
- -24.3%
- ROCE
- -24.2%
- ROIC
- -20.8%
- ROA
- -21.5%
- Asset turnover
- 0.06
Growth
- RevenueFY2025, the latest fiscal year in the company's growth history.
- $18.7M
- Revenue growth, 1YFY2025, the latest fiscal year in the company's growth history.
- -29.3%
- Revenue CAGR, 3YFY2025, the latest fiscal year in the company's growth history.
- -31.9%
- Net profit growth, 1YFY2025, the latest fiscal year in the company's growth history.
- 4.4%
- Free cash flowFY2025, the latest fiscal year in the company's growth history.
- -$37.0M
Solvency
- Current ratio
- 4.02
- Debt / Equity
- 0.08
- Debt / Assets
- 0.07
- CFO / Net profit
- 0.56
- Cash / Market cap
- 6.6%
Where the revenue went
FY2025 ended in a loss, so the lines are listed rather than drawn as a flow.
| Line | FY2025 |
|---|---|
| Revenue | $18.7M |
| Cost of revenue | $300.0k |
| Gross profit | $18.4M |
| Operating expenses | $87.3M |
| Research and development | $47.8M |
| Selling, general and administrative | $29.2M |
| Operating income | -$69.0M |
| Interest and other | $2.7M |
| Pretax income | -$66.3M |
| Tax and other | -$1.5M |
| Net income | -$64.8M |
Revenue and net profit
Revenue fell 29.3% in FY2025; net profit is the dashed line.
| Date | Revenue | Net profit |
|---|---|---|
| FY2022 | $59.1M | -$22.3M |
| FY2023 | $34.2M | -$50.6M |
| FY2024 | $26.4M | -$62.0M |
| FY2025 | $18.7M | -$64.8M |
Cash flows
FY2025: -$36.5M from operations, -$37.0M free after investment (dashed).
| Date | Operating cash flow | Free cash flow |
|---|---|---|
| FY2022 | -$3.6M | -$20.8M |
| FY2023 | $2.3M | $703.0k |
| FY2024 | -$39.7M | -$41.5M |
| FY2025 | -$36.5M | -$37.0M |
Growth
Latest fiscal year 2025: each figure with its change over the year before.
- Revenue
- $18.7M-29.3%1Y
- EBITDA
- -$47.2M
- Net profit
- -$64.8M
- Cash from operations
- -$36.5M
- Free cash flow
- -$37.0M
- Revenue CAGR, 3Y
- -31.9%
| Year | Revenue | EBITDA | Net profit | FCF | ROE | Revenue growth 1Y | Net profit growth 1Y |
|---|---|---|---|---|---|---|---|
| FY2025 | $18.7M | -$47.2M | -$64.8M | -$37.0M | -24.3% | -29.3% | +4.4% |
Monthly returns
Month-by-month returns of OABI across the years, with the seasonal pattern.
Balance sheet
What the company owns and owes at the end of FY2025.
| Line | FY2025 |
|---|---|
| Assets | $300.9M |
| Current assets | $65.3M |
| Non-current assets | $235.6M |
| Liabilities | $33.9M |
| Current liabilities | $16.3M |
| Non-current liabilities | $17.6M |
| Equity | $267.0M |
| Paid-in capital | $433.2M |
| Retained earnings | -$166.2M |
Market cap against peers
8 peers: same sector, nearest by size.
Peers map
Healthcare companies placed by value, growth and quality; OABI highlighted.
P/E against peers
Most of this group is loss-making, so EV / Sales is compared for the companies without a P/E.
Not shown (no positive earnings and no EV / Sales): Compass Therapeutics, Inc., Benitec Biopharma Inc., Lexeo Therapeutics, Inc.
Peer comparison
Same-sector peers by market cap, with the median.
| Company | Market cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|
| OmniAb, Inc.OABIthis company | $385.6M | -6.0x | 1.4x | -24.3% | -8.1x |
| Community Health Systems, Inc.CYH | $393.2M | 0.8x | -0.3x | -36.5% | 5.5x |
| TruBridge, Inc.TBRG | $390.7M | 89.7x | 2.2x | 2.4% | 12.5x |
| Compass Therapeutics, Inc.CMPX | $383.6M | -5.8x | 1.9x | -33.8% | -5.1x |
| Benitec Biopharma Inc.BNTC | $379.6M | -10.0x | 3.9x | -39.0% | -6.8x |
| Viemed Healthcare, Inc.VMD | $377.2M | 25.3x | 2.7x | 10.6% | 7.4x |
| CapsoVision, Inc.CV | $376.7M | -14.9x | 28.4x | -190.9% | -14.7x |
| Vanda Pharmaceuticals Inc.VNDA | $375.8M | — | 1.1x | -67.4% | — |
| Lexeo Therapeutics, Inc.LXEO | $375.3M | -3.8x | 1.5x | -40.5% | -3.3x |
| Peer median | — | -3.8x | 2.1x | -37.7% | -3.3x |
Year-to-date ROI
OABI since 1 January, against earlier years.
Historical volatility
OABI's day-to-day swings over 30, 60 and 180 days.
Financial statements
Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.
Consolidated figures in USD, fiscal years, newest first.
Operating margin by fiscal year
| Date | Operating margin |
|---|---|
| FY2022 | -45.1% |
| FY2023 | -203.2% |
| FY2024 | -282.3% |
| FY2025 | -369.4% |
| Line | FY2025 |
|---|---|
| RevenueTotal Revenue | $18.7M |
| Cost of revenueCost Of Revenue | $300.0k |
| Gross profitGross Profit | $18.4M |
| Operating expensesOperating Expense | $87.3M |
| Research and developmentResearch And Development | $47.8M |
| Selling, general and administrativeSelling General And Administration | $29.2M |
| Other operating expensesOther Operating Expenses | -$2.5M |
| Depreciation and amortisationDepreciation And Amortization In Income Statement | $12.9M |
| Depreciation, amortisation and depletionDepreciation Amortization Depletion Income Statement | $12.9M |
| Amortization | $12.9M |
| Amortisation of intangiblesAmortization Of Intangibles Income Statement | $12.9M |
| Total expensesTotal Expenses | $87.6M |
| Operating incomeOperating Income | -$69.0M |
| Interest and other | |
| Pretax incomePretax Income | -$66.3M |
| TaxTax Provision | -$1.5M |
| Net incomeNet Income | -$64.8M |
| Per share | |
| Supplementary |
| Line | FY2025 |
|---|---|
| AssetsTotal Assets | $300.9M |
| Current assetsCurrent Assets | $65.3M |
| Non-current assetsTotal Non Current Assets | $235.6M |
| LiabilitiesTotal Liabilities Net Minority Interest | $33.9M |
| Current liabilitiesCurrent Liabilities | $16.3M |
| Non-current liabilitiesTotal Non Current Liabilities Net Minority Interest | $17.6M |
| EquityTotal Equity Gross Minority Interest | $267.0M |
| Supplementary |
| Line | FY2025 |
|---|---|
| Operating cash flowOperating Cash Flow | -$36.5M |
| Cash from continuing operationsCash Flow From Continuing Operating Activities | -$36.5M |
| Net income, continuing operationsNet Income From Continuing Operations | -$64.8M |
| Depreciation and amortisationDepreciation And Amortization | $21.8M |
| Depreciation, amortisation and depletionDepreciation Amortization Depletion | $21.8M |
| Amortization of securitiesAmortization Of Securities | -$860.0k |
| Stock-based compensationStock Based Compensation | $15.8M |
| Deferred taxDeferred Tax | -$1.5M |
| Deferred income taxDeferred Income Tax | -$1.5M |
| Operating gains and lossesOperating Gains Losses | -$3.0M |
| Gain loss on investment securitiesGain Loss On Investment Securities | — |
| Gain loss on sale of PP&EGain Loss On Sale Of PPE | -$3.0M |
| Change in working capitalChange In Working Capital | -$5.0M |
| Other non-cash itemsOther Non Cash Items | $1.1M |
| Investing cash flowInvesting Cash Flow | $6.5M |
| Cash from continuing investingCash Flow From Continuing Investing Activities | $6.5M |
| Capital expenditureCapital Expenditure | -$560.0k |
| Purchase of PP&EPurchase Of PPE | -$560.0k |
| Net PP&E purchases and salesNet PPE Purchase And Sale | -$560.0k |
| AcquisitionsPurchase Of Business | — |
| Net acquisitions and disposalsNet Business Purchase And Sale | — |
| Purchase of investmentsPurchase Of Investment | -$46.9M |
| Sale of investmentsSale Of Investment | $50.9M |
| Net investment purchases and salesNet Investment Purchase And Sale | $4.0M |
| Sale of intangiblesSale Of Intangibles | — |
| Net intangibles purchases and salesNet Intangibles Purchase And Sale | — |
| Other investing changesNet Other Investing Changes | $3.0M |
| Financing cash flowFinancing Cash Flow | $27.9M |
| Cash from continuing financingCash Flow From Continuing Financing Activities | $27.9M |
| Shares issuedIssuance Of Capital Stock | $28.2M |
| Common stock issuedCommon Stock Issuance | $28.2M |
| Net common stock issuedNet Common Stock Issuance | $28.2M |
| Stock options exercisedProceeds From Stock Option Exercised | $490.0k |
| Other financing chargesNet Other Financing Charges | -$770.0k |
| Change in cashChanges In Cash | -$2.1M |
| Cash at the start of the yearBeginning Cash Position | $28.2M |
| Cash at the end of the yearEnd Cash Position | $26.1M |
| Free cash flowFree Cash Flow | -$37.0M |
| Supplemental |
Learn while you research
Academy chapters picked for OmniAb, Inc. and the metrics on this page.
- 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
- 02 Stock Market RisksSmall caps carry concentrated, idiosyncratic risk, learn to manage it.6 min read
- 03 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
- 04 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
- 05 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read